Current Actions
Response to USPSTF draft guideline changes for PSA screening in men
The United States Preventive Services Task Force (USPSTF) recommended changes to the screening guidelines for prostate cancer. The task force recommended against PSA screening for high-risk and average-risk men of any age. FORCE issued a position statement and is encouraging public commentary concerning these guideline changes.
The FDA recently ruled that Avastin be removed from the list of approved therapies for metastatic breast cancer. While FORCE respects the FDA’s decision, we are disappointed with this outcome. FORCE has prepared a statement in response to the FDA recent ruling.
The American Civil Liberties Union (ACLU) is representing several plaintiffs in a lawsuit against Myriad Genetics, holder of the patent for the BRCA 1 and BRCA 2 genes. FORCE is concerned that the patenting of the BRCA genes has led to increased cost of BRCA testing, decreased access to testing, inability for patients to obtain second opinions on genetic testing, and has placed restrictions on hereditary cancer research. FORCE has filed an amicus brief (friend of the court) in favor of the lawsuit.
Page updated 10/30/11
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.